Startseite Kongressberichte 2021 2021 SAN ANTONIO BREAST CANCER SYMPOSIUM General Session 1

General Session 1 (available abstracts)

Publication Number: GS1-01:

KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

Peter Schmid, Javier Cortes, Rebecca Dent, et al.

The authors conclude that the EFS sensitivity analyzes revealed a robust and generally consistent treatment benefit of neoadjuvant pembro + chemotherapy followed by adjuvant pembro across a wide range of patient subgroups in previously untreated, non-metastatic triple-negative breast cancer.

 

Publication Number: GS1-02

Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Javier Cortes, David W. Cescon, Hope S. Rugo, et al.

The authors conclude that the study shows that CPS ≥ 10 is a reasonable cut-off to define the patient population with metastatic triple negative breast cancer who could benefit from Pembro + chemotherapy.

 

Publication Number: GS1-05

Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study 

Ian Krop, Dejan Juric, Toshio Shimizu, et al.

The authors conclude that Dato-DXd has shown promise in antitumor activity in patients with previously treated advanced / metastatic triple negative breast cancer. The security profile is manageable.

 

Publication Number: GS1-06

A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer 

Binghe Xu, Qingyuan Zhang, Xichun Hu, et al.

The authors conclude that compared with exemestane monotherapy, entinostat plus exemestane significantly improved progression-free survival in HR-positive, HER2-negative breast cancer that had progressed after previous endocrine therapy. The combination was generally tolerated and may offer important clinical benefit in these patients.

 

Publication Number: GS1-07 

Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial 

Michael Gnant, Amylou C Dueck, Sophie Frantal, et al.

The authors conclude that this analysis of the PALLAS study shows that adding 2 years of palbociclib to ongoing adjuvant endocrine therapy did not improve survival endpoints for patients with HR + / HER2-eBC stage II-III.

 

Publication Number: GS1-09 

Inhibition of GPX4 induces preferential death of p53-mutant triple-negative breast cancer cells 

William M Tahaney, Jing Qian, Reid Powell, et al.

With their studies, the authors provide the scientific basis for the further development of ferroptosis inducers for the targeted treatment of p53-mutated breast cancer. For more information see the abstract.